日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer

BRCA1/2、PALB2 突变与 HR+ 转移性乳腺癌一线 CDK4/6 抑制剂疗效

Guinel, Timothé; Lusque, Amélie; Mailliez, Audrey; Massard, Vincent; Jacot, William; Guiu, Severine; de la Motte Rouge, Thibault; Brain, Etienne; Desmoulins, Isabelle; Arnedos, Monica; Bailleux, Caroline; Goncalves, Anthony; Levy, Christelle; Bachelot, Thomas; Bosquet, Lise; Delaloge, Suzette; Frénel, Jean-Sébastien

Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort

ESME-MBC队列中HR阳性/HER2阴性转移性乳腺癌患者在接受CDK4/6抑制剂治疗后疾病进展的真实世界治疗模式和疗效

Varnier, R; Pérol, D; Jacot, W; Mailliez, A; Diéras, V; Dalenc, F; Gonçalves, A; Levy, C; Arnedos, M; Frenel, J-S; Bailleux, C; Massard, V; Brain, E; Sauterey, B; Savoye, A-M; Bosquet, L; Thery, J-C; Petit, T; Bachelot, T; Grinda, T; Ray-Coquard, I

Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer

在接受曲妥珠单抗-德鲁西替康治疗后,图卡替尼联合治疗ERBB2阳性转移性乳腺癌患者

Frenel, Jean-Sebastien; Zeghondy, Jean; Guérin-Charbonnel, Catherine; Mailliez, Audrey; Volant, Elsa; Poumeaud, François; Patsouris, Anne; Arnedos, Monica; Bailleux, Caroline; Cabal, Julie; Galland, Loick; de Nonneville, Alexandre; Guiu, Séverine; Dalenc, Florence; Pistilli, Barbara; Bachelot, Thomas; Pierga, Jean-Yves; Le Du, Fanny; Bocquet, François; Larrouquere, Louis; Loirat, Delphine

Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort

法国 ESME 队列中 HER2 低表达转移性乳腺癌脑转移和/或软脑膜转移的发生率和预后

Epaillard, N; Lusque, A; Jacot, W; Mailliez, A; Bachelot, T; Arnedos, M; Le Du, F; Brain, E; Ferrero, J M; Massard, V; Desmoulins, I; Mouret-Reynier, M A; Levy, C; Gonçalves, A; Leheurteur, M; Petit, T; Filleron, T; Bosquet, L; Pistilli, B; Frenel, J S

Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?

Elacestrant 用于 ESR1 突变、内分泌反应性转移性乳腺癌:卫生当局是否应考虑事后数据以决定优先使用?

Valenza, C; Trapani, D; Bidard, F-C; Gligorov, J; Cortés, J; Turner, N; Dalenc, F; Penault-Llorca, F; Freyer, G; Arnedos, M; Villanueva, C; Loibl, S; Pistilli, B; Curigliano, G

Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data

抗雄激素治疗雄激素受体阳性三阴性转移性乳腺癌的疗效:真实世界数据

Rhanine, Yasmine; Bonnefoi, Hervé; Goncalves, Anthony; Debled, Marc; Le Moulec, Sylvestre; Bonichon, Nathalie; Macgrogan, Gaetan; Arnedos, Monica; Dubroca-Dehez, Bénédicte; Grellety, Thomas

p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane

p4EBP1染色可预测接受依维莫司和依西美坦治疗的ER阳性内分泌耐药转移性乳腺癌患者的预后

Vanacker, Hélène; Treilleux, Isabelle; Schiffler, Camille; Bieche, Ivan; Campone, Mario; Patsouris, Anne; Arnedos, Monica; Cottu, Paul H; Jacquin, Jean-Philippe; Dalenc, Florence; Pinton, Antoine; Servant, Nicolas; Attignon, Valéry; Rouleau, Etienne; Morel, Alain; Legrand, François; Jimenez, Marta; Andre, Fabrice; Bachelot, Thomas

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

奈拉替尼+氟维司群+曲妥珠单抗治疗HR阳性、HER2阴性、HER2突变型转移性乳腺癌:SUMMIT试验的结果和生物标志物分析

Jhaveri, K; Eli, L D; Wildiers, H; Hurvitz, S A; Guerrero-Zotano, A; Unni, N; Brufsky, A; Park, H; Waisman, J; Yang, E S; Spanggaard, I; Reid, S; Burkard, M E; Vinayak, S; Prat, A; Arnedos, M; Bidard, F-C; Loi, S; Crown, J; Bhave, M; Piha-Paul, S A; Suga, J M; Chia, S; Saura, C; Garcia-Saenz, J Á; Gambardella, V; de Miguel, M J; Gal-Yam, E N; Rapael, A; Stemmer, S M; Ma, C; Hanker, A B; Ye, D; Goldman, J W; Bose, R; Peterson, L; Bell, J S K; Frazier, A; DiPrimeo, D; Wong, A; Arteaga, C L; Solit, D B

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

奈拉替尼对HER2突变型晚期胆道癌患者的抗肿瘤活性

Harding, James J; Piha-Paul, Sarina A; Shah, Ronak H; Murphy, Jessica J; Cleary, James M; Shapiro, Geoffrey I; Quinn, David I; Braña, Irene; Moreno, Victor; Borad, Mitesh; Loi, Sherene; Spanggaard, Iben; Park, Haeseong; Ford, James M; Arnedos, Mónica; Stemmer, Salomon M; de la Fouchardiere, Christelle; Fountzilas, Christos; Zhang, Jie; DiPrimeo, Daniel; Savin, Casey; Duygu Selcuklu, S; Berger, Michael F; Eli, Lisa D; Meric-Bernstam, Funda; Jhaveri, Komal; Solit, David B; Abou-Alfa, Ghassan K

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

OlympiA III期临床试验中,奥拉帕尼辅助治疗对携带BRCA1/2种系致病性变异的高危早期乳腺癌患者的总生存期

Geyer, C E Jr; Garber, J E; Gelber, R D; Yothers, G; Taboada, M; Ross, L; Rastogi, P; Cui, K; Arahmani, A; Aktan, G; Armstrong, A C; Arnedos, M; Balmaña, J; Bergh, J; Bliss, J; Delaloge, S; Domchek, S M; Eisen, A; Elsafy, F; Fein, L E; Fielding, A; Ford, J M; Friedman, S; Gelmon, K A; Gianni, L; Gnant, M; Hollingsworth, S J; Im, S-A; Jager, A; Jóhannsson, Ó Þ; Lakhani, S R; Janni, W; Linderholm, B; Liu, T-W; Loman, N; Korde, L; Loibl, S; Lucas, P C; Marmé, F; Martinez de Dueñas, E; McConnell, R; Phillips, K-A; Piccart, M; Rossi, G; Schmutzler, R; Senkus, E; Shao, Z; Sharma, P; Singer, C F; Španić, T; Stickeler, E; Toi, M; Traina, T A; Viale, G; Zoppoli, G; Park, Y H; Yerushalmi, R; Yang, H; Pang, D; Jung, K H; Mailliez, A; Fan, Z; Tennevet, I; Zhang, J; Nagy, T; Sonke, G S; Sun, Q; Parton, M; Colleoni, M A; Schmidt, M; Brufsky, A M; Razaq, W; Kaufman, B; Cameron, D; Campbell, C; Tutt, A N J